G1 Therapeutics, a commercial-stage oncology biopharmaceutical company with a mission to develop and deliver next-generation therapies to improve the lives of individuals impacted by cancer, will be hosting a webcast and conference call on May 1, 2024. The event will provide a financial and corporate update for the first quarter of 2024.
Interested individuals can register for the event and receive the necessary dial-in information by following the provided link on G1 Therapeutics’ website. It is recommended to join the event 10 minutes prior to the start time. A live and archived webcast will be available on the Events & Presentations page of G1 Therapeutics’ website for those who are unable to attend the live event.
G1 Therapeutics’ first commercial product is COSELA® (trilaciclib), which is being used in combination with cytotoxic therapies and/or immunotherapy for conditions with high unmet needs, such as triple-negative breast cancer and extensive stage small cell lung cancer. The company aims to provide innovative therapeutic solutions for cancer patients.
For further information or inquiries, individuals can contact G1 Therapeutics’ Communications Officer and Vice President of Investor Relations and Corporate Communications, Will Roberts, at (919) 907-1944 or via email at wroberts@g1therapeutics.com. Trademarks owned by G1 Therapeutics include G1 Therapeutics®, COSELA®, and their respective logos.